GH Research stock hits all-time high at 31.41 USD
GH Research PLC (GHRS) shares hit an all-time high of $31.41, up 146.9% over the past year, with market cap around $2.1B, according to Investing.com/InvestingPro. The article also cites Phase 2a results for inhaled mebufotenin (GH001) in postpartum depression, and Q1 2026 updates. Cantor Fitzgerald raised its price target to $35; others adjusted targets to $65 and $39.
How this was made
The 30-second read
Why it matters
For traders, the actionable element is the combination of a new price milestone (all-time high) with specific clinical milestones (Phase 2a remission timing and Phase 3 dose selection) and analyst target changes.
Market read
GHRS is presented as a momentum trade tied to psychedelic-therapy clinical progress and bullish sell-side revisions, but with dilution risk noted.
What to watch
The piece does not provide trial sample size, statistical significance, or safety details, which are key for underwriting Phase 3 success and valuation.
Background
The article frames GH Research PLC’s stock surge alongside clinical development updates for inhaled mebufotenin (GH001) in postpartum depression and progress toward a global Phase 3 program.
Ticker impact
GH Research PLC hit an all-time high at $31.41 and the article cites Phase 2a GH001 postpartum depression results plus Phase 3 dose selection.
Near-term upside bias from clinical progress and bullish analyst target changes, with volatility risk given dilution mention.
The text links the price milestone to Phase 2a remission within two hours through Day 8 and to Phase 3 pivotal dose selection, plus multiple analyst target revisions.
Market effects
Reinforces positive sentiment toward psychedelic-therapy development timelines and read-through for similar assets.
No clear regional-specific impact beyond US-listed small/mid-cap biotech sentiment.
Limited; the only cross-sector item is a reported interest in Atai Life Sciences, which is framed as sector outlook support.
Counterpoint
The article also flags share-count dilution (H.C. Wainwright PT cut), so the rally could be partially offset by dilution and execution risk in Phase 3.
Key entities
- companyGH Research PLC
Subject of the article, with an all-time high price and cited GH001 clinical and program updates.
- companyEli Lilly
Mentioned as having interest in acquiring Atai Life Sciences, which is presented as sector read-through.
- companyAtai Life Sciences
Referenced as a potential acquisition target with similar therapeutic targets to GH001.
